Clinical Trials · NCT06484114
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
- Phase
- N/A
- Recruitment status
- Active Not Recruiting
- Sponsor
- Fractyl Health Inc.
- Enrollment
- 315
- Start date
- Sep 2024
- Locations
- 32 sites, United States
- Primary endpoint
- To demonstrate that Revita DMR is superior to sham in percent change in body weight from baseline to week 26